Paltusotine tablets
Sponsors
Crinetics Pharmaceuticals Inc.
Conditions
AcromegalyCarcinoid Syndrome
Phase 2
An open label, long-term extension study to evaluate the safety and efficacy of CRN00808 in subjects with acromegaly (ACROBAT ADVANCE)
RecruitingCTIS2024-511921-75-00
Start: 2020-02-19Target: 10Updated: 2025-07-29
A Randomized, Parallel Group Study to Evaluate the Safety, Pharmacokinetics, and Dose Response of Paltusotine Treatment in Subjects with Carcinoid Syndrome
RecruitingCTIS2024-511922-30-00
Start: 2023-05-11Target: 2Updated: 2025-08-18
Phase 3
A Randomized, Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects with Acromegaly Treated with Long-acting Somatostatin Receptor Ligands
Active, not recruitingCTIS2024-511925-71-00
Start: 2021-08-05Target: 20Updated: 2025-10-09
A Randomized, Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects with Non-pharmacologically Treated Acromegaly (PATHFNDR-2)
Active, not recruitingCTIS2024-511924-15-00
Start: 2022-04-29Target: 61Updated: 2025-11-11